Review of the drugs:

Enbrel and Remicade have begun to suffer impacts of generic drugs, with market shares largely reducing.
As the third anti-TNFα monoclonal antibody marketed and the first fully human antibody, Humira has taken 14 clinical indications upon its advantages in clinical efficacy (the above two separately have 5 and 8) and advanced triumphantly on the market, to become a king.
FDA has approved the two biosimilars of Humira: Amgen’s Amjevita (adalimumab-atto, September 23, 2016) and Ogivri (trastuzumab-dkst, August 25, 2017), however, AbbVie managed to shut them out by reaching a settlement with Amgen and accusing Boehringer Ingelheim of patent infringement, therefore, Humira will still be unshakeable in the next years.
Although "envied" by other drugs, Humira makes a "a wry smile": the sunset is so beautiful, but that evening (of Humira) is on the way!
Cimzia and Simponi were marketed later than the above three monoclonal antibodies, and their sales are expected to continue to rise to reach USD 2 billion before patent expiration, however, the overall market of anti-TNFα monoclonal antibodies becomes increasingly saturated and tumultuous due to impacts of generic drugs and competition from latecomers, and is difficult to continue the peak of the above 3 all exceeding USD 10 billion sales.
|
Marketing time |
Company |
Pharmaceutical product |
Target |
2015 sales |
2016 sales |
2017 sales |
Trend |
|
2002 |
Amgen/Pfizer/Takeda |
Enbrel (etanercept) |
TNFα fusion protein |
88.97 |
88.74 |
80.78 |
-9% |
|
2004 |
J & J/MSD/Mitsubishi Tanabe |
Remicade (infliximab) |
Anti-TNFα monoclonal antibody |
83.55 |
82.34 |
77.28 |
-9.30% |
|
2005 |
AbbVie |
Humira (adalimumab) |
Anti-TNFα monoclonal antibody |
140.12 |
160.78 |
184.27 |
14.60% |
|
2009 |
J & J |
Simponi/Simponi Aria (golimumab) |
Anti-TNFα monoclonal antibody |
13.28 |
17.45 |
18.33 |
Read More
Related News
Predicted Top 5 Worldwide Selling Generic or Biosimilar Drugs in 2025
David Orchard-Webb July 8, 2025
Skill development programme on PV launched
financialexpress January 20, 2017
Mallinckrodt and FTC Resolve Questcor Matter
americanpharmaceuticalreview January 20, 2017 You may like
Supply nitrile rubber suction cup HFG-200 vacuum suction cup spreader high temperature suction cup
Tempered glass suction cup hanger, glass deep processing handling lifting suction cup, glass 90 degree flip suction crane
Orforglipron
3 tons of aluminum plate vacuum suction cup hanger can set high quality plate suction cup hanger
Vacuum suction cup hanger steel plate high temperature aluminum plate suction cup titanium plate and other metal plate suction cup under 30 tons
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Nurah Ekhlaque
Sep 19, 2025
Digitalization in Procurement: From AI Forecasting to Blockchain Traceability
Saher Haider
Sep 19, 2025
Methodology Validation in Chinese Pharmacopoeia 2025: How to Report Accuracy and Precision
Xing Xing
Sep 12, 2025
|










(All Rights Reserved)